SEC Comment Letter 0000000000-23-012334 to Tharimmune, Inc. (THAR) (CIK 0001861657) (THAR)
Tharimmune, Inc. (THAR) (CIK 0001861657)
Date: Nov. 10, 2023 · CIK: 0001861657 · Accession: 0000000000-23-012334
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275350
Letter
United States securities and exchange commission logo November 9, 2023 Randy Milby Chief Executive Officer Tharimmune, Inc. 1200 Route 22 East, Suite 2000 Bridgewater, NJ 08807 Re:Tharimmune, Inc. Registration Statement on Form S-1 Filed November 6, 2023 File No. 333-275350 Dear Randy Milby: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeff Fessler, Esq.
Show Raw Text
United States securities and exchange commission logo
November 9, 2023
Randy Milby
Chief Executive Officer
Tharimmune, Inc.
1200 Route 22 East, Suite 2000
Bridgewater, NJ 08807
Re:Tharimmune, Inc.
Registration Statement on Form S-1
Filed November 6, 2023
File No. 333-275350
Dear Randy Milby:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeff Fessler, Esq.